We are pleased to announce that WuXi NextCODE’s Shanghai sequencing facility has been accredited by the College of American Pathologists (CAP) and become the first such laboratory in China to be licensed by the State of California, enabling it to process samples from California. WuXi NextCODE is also the only sequencing facility in China with CLIA (Clinial Laboratory Improvement Amendments) certification from the US Centers for Medicare and Medicaid (CMS).  We offers the global gold standard in next generation sequencing through our Shanghai laboratory.  These latest accreditations underscore that quality and our commitment to meet the exacting standards and regulatory requirements of our clinical and research clients and partners, in China and worldwide.



Related articles:

  1. Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project
  2. Sidra Selects WuXi NextCODE to Power Population Genomics and Precision Medicine in Qatar
  3. WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China